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Pharmaceutical Care Management Association v. Rutledge
Abstract
On June 8, 2018 the federal Eighth Circuit Court of Appeals announced its decision concerning Arkansas'
attempt to regulate perceived unfair payment practices of pharmacy benefit managers (PBMs) in the case

Pharmaceutical Care Management Association v. Rutledge.1 Because pharmacies across the country
face similar problems, and this ruling may influence other federal appellate courts, review and discussion
is useful for the purpose of making strategic decisions.
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Pharmaceutical Care Management Association v. Rutledge
John Crean, PharmD Candidate, Wegmans School of Pharmacy, St John Fisher College
Karl G. William s, RPh, LLM, JD, Professor Pharm acy Ethics and l aw, Wegm ans School of Pharmacy,
St John Fisher College
On June 8, 2018 the federa l Eighth Circuit Court
of Appeals announced

its decision concerning

Arkansas' attempt to regulate perceived unfair
payment

practices of pharmacy benefit managers

(PBMs) in the case Pharmaceutical Care Management
1

Association v. Rutledge. Because pharmacies across
the country face similar problems, and this ruling
may influence other federa l appellate courts, review
and discussion is useful fo r the purpose of making
strategic decisions.

pharmacies

allows

the

ability

to

"decline

to

dispense" when the pharmacy would otherwise be
dispensing at less the cost.
Pharmaceutical Care Management Association
(PCMA) sued the state alleging that Arkansas key
provisions were "preempted" by both Employee Retirement Income Security Act (ERISA) and the
Medicare Modernization Act's Medicare Part D. The
federa l District Court fo r the Eastern District of
Arkansas ruled the state statute preempted by ERISA,

Background: Pharmacy benefi t managers, among

but not preempted by Medicare Part D.3 PCMA

other services provided to plan "sponsors" (health

appealed the Medicare Part D ruling, and the state

insurance plans, unions, state Medicaid providers,

cross-appealed the ERISA ruling to the federa l Court

and Medicare Part D), compensate pharmacies for

of Appeals for the Eighth Circuit.

generic medication based on a "maximum allowable
cost" fo r each medication. Maximum allowable cost
("MAC") lists offered to pharmacies without negotiation, and remain in effect for the contract period.
Different manufacturers will charge different prices
for interchangeable generic drugs; in theory, MAC
pricing creates an incentive fo r pharmacies to
purchase

the

least

costly

generic

medication

available in the market. However, because the MAC
price is fixed, and not subject to changes in cost,
pharmacies might often be required to dispense
medication at a price that is lower than their actual
cost. The Arkansas state legislature attempted to
address disastrous effects this was having on
independent

pharmacies.

Act

9002

provided

compensation for generic drugs at a price equal to

"Preemption doctrine" is the pivotal

legal

principle in this case. Rooted in the Supremacy
4

Clause of the US Constitution, the legal doctrine
provides that when the federa l law 'intends' to
preempt state law, federa l law controls. Congress'
intent may be implied or expressed. Preemption may
be inferred when the federal law is so comprehensive
that any state attempt to regulate would be in
conflict or defeat the intended regulation. Congress
may also expressly preempt state laws, by specifically
stating in statute specific state actions that are off
limits. ERISA and Medicare Part D both expressly
preempt conflicting state actions. In this case the
courts were asked to decide whether the elements of
Act 900 were distinguishable from ERISA and
Medicare Part D.

or higher that the pharmacies' cost based on the
invoice from the wholesaler. The act also requires
PBMs to update their Maximum Allowable Cost
(MAC) list within seven days from the time of a
certain increase in acquisition cost. Act 900 further

ERISA: Enacted in 1974, the purpose of ERISA
was setting

minimum standards for employer-

sponsored health and pension plans. ERISA case law
long ago established that a "state law is preempted if
{continued on page 30)
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(continued from page 29)

it 'relates to'" or has "a connection with reference to

reasoning that the negotiated MAC prices were

such a plan"; 5 a very broad standard. In this case, the

insubstantial and that the alternative pricing structure

District court relied on legal precedent from an Iowa

was to provide transparency and to control the PBM

case (in the same federal circuit as Arkansas).6 The

practices. Also, declining to dispense on a single

court ruled the Iowa law preempted because it had a

occasion, the District court reasoned, does not take

prohibited "reference to" ERISA and it interfered with

the pharmacy out of the network and deprive the

"national uniform plan administration". Specifically,

patient of convenient access. As a result, the lower

the

Iowa

statute

required

PBMs

to

provide

information about their pricing methodologies and
limited the types of drugs PBMs could apply MAC
pricing to. By regulating the conduct of PBMs
administering or managing pharmacy benefits, the
court held that the Iowa statute "both explicitly and
implicitly referred to ERISA".

The District court

determined the Iowa precedent to control the outcome in Arkansas because PBMs "administer benefits

court ruled that Act 900 did not interfere and not
preempted by Medicare Part D.
The Eighth Circuit overruled the decision of the
District court, criticizing the lower court for its
'cursory' reasoning. The appellate court reasoned
that Act 900 essentially replaces the negotiated MAC
price with the pharmacy acquisition cost when the
MAC rate is below the pharmacy's invoice cost. thus
acting "with respect to" 'negotiated' MAC prices

for 'covered entities' ... which include health benefit
plans", the object of ERISA. That is, ERISA provides

Medicare Part

D has a Pharmacy Access

shelter for a PBM, not because they are a health plan,

Standard that gives recipients access to pharmacies.

but due to their contractual relationship with a health

A PBM "shall secure the participation in its network of

plan. With little additional analysis, the Eighth Circuit
appellate court agreed, upholding the lower court's
decision.

a sufficient number of pharmacies that dispense
drugs directly to patients to ensure convenient
access." The district court decided that Act 900 did
not act with respect to that pharmacy access stand-

Medicare Part D: The Medicare Modernization
Act (Medicare Part D) prohibits interference with any
government entity in negotiations between PBMs
and pharmacies. Popularly known as the "noninterference clause'} explicit preemption exists for
state laws that act "with respect to" standards
established by Congress or CMS. The Medicare Part

ard because the decline-to-dispense provisions do
not render a pharmacy as out of network. The Eighth
Circuit court of Appeals disagreed. The Eighth Circuit
decided that a pharmacy that refused to dispense
becomes "in effect" an out-of-network pharma cy for
that transaction. This is enough, reasoned the
appellate court, to preempt the Arkansa s state law.

D statute requires the creation of a network of
pharmacies "to ensure convenient access" 8 by

Comments: The Eighth Circuit's rulings have

patients. Also, CMS regulations provide a definition

effectively gutt ed the Arkansas law with extremely

for "negotiated prices" (the MAC list).

superficial reasoning

regarding

both ERISA and

Medicare Part D. A contractual relationship with a
PCMA argued that Act 900's regulation of prices
interfered with both the negotiated prices standard
and the convenient access t o pharmacy provisions,
and were preempted interference by the state. The
district court disagreed with this interpretation,

health care plan sponsor does not make a PBM a
health plan. They are merely a conduit that is not
worthy of derivative shelter under the ERISA law.
Also, Arkansas was correct that "negotiation" of MAC
(continued on page 31)
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prices had no substantial meaning; every pharmacy
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